Melatonin in the prevention of cisplatin-induced acute nephrotoxicity: a randomized, controlled clinical trial

Sara Karvan , Alireza Sadeghi, Pegah Farrokhi, Amirabbass Nekouee, Mehran Sharifi, Azadeh Moghaddas

Abstract


Background and purpose: Cisplatin-induced nephrotoxicity (CisIN) remains the most dose-limiting adverse effect of its clinical use. The protective effects of melatonin on CisIN have been addressed in several non-clinical and animal studies. This study aimed at investigating the potential effects of melatonin on the prevention of CisIN in human.

Experimental approach: Our study was a randomized controlled clinical trial, performed on 66 eligible patients in two groups of melatonin or control (no intervention). Melatonin was administrated daily at a dose of 20 mg for 5 days to the patients receiving cisplatin-containing regimens along with the standard protocol of CisIN prevention. Patient demographic information, blood and urinary indices of nitrogen, creatinine, and electrolytes such as sodium, potassium, magnesium as well as neutrophil gelatinase-associated lipocalin were measured in both groups at the baseline, 24 h and five days after melatonin administration.

Findings/Results: Cisplatin administration resulted in significant magnesium and potassium loss in patients with cancer. In comparison with the control group, the prevalence of acute renal injury and the rate of urinary magnesium and potassium loss improved with melatonin administration; however, the results were not statistically significant. Tolerable side effects such as daytime drowsiness, nausea, and vomiting were reported in the melatonin group.

Conclusion and implications: Although pretreatment with melatonin led to amelioration in urinary electrolyte loss due to CisIN, it failed to show a positive result on acute renal injury prevention. Future well-designed studies with a longer duration of follow-up, larger sample sizes, and higher doses of melatonin are warranted.


Keywords


Cisplatin; Clinical trial; Electrolyte; Melatonin; Nephrotoxicity.

Full Text:

PDF

References


Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol. 2018;31(1):15-25.

DOI: 10.1007/s40620-017-0392-z.

Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep. 2003;10(6):1663-1682.

DOI: 10.3892/or.10.6.1663.

Li J, Gui Y, Ren J, Liu X, Feng Y, Zeng Z, et al. Metformin protects against cisplatin-induced tubular cell apoptosis and acute kidney injury via AMPKα-regulated autophagy induction. Sci Rep. 2016; 6(1):1-11.

DOI: 10.1038/srep23975.

Maliakel DM, Kagiya TV, Nair CKK. Prevention of cisplatin-induced nephrotoxicity by glucosides of ascorbic acid and α-tocopherol. Exp Toxicol Pathol. 2008;60(6):521-527.

DOI: 10.1016/j.etp.2008.04.015.

Karademir LD, Dogruel F, Kocyigit I, Yazici C, Unal A, Sipahioglu MH, et al. The efficacy of theophylline in preventing cisplatin-related nephrotoxicity in patients with cancer. Ren Fail. 2016;38(5):806-814.

DOI: 10.3109/0886022X.2016.1163154.

Huang S, You J, Wang K, Li Y, Zhang Y, Wei H, et al. N-acetylcysteine attenuates cisplatin-induced acute kidney injury by inhibiting the C5a receptor. Biomed Res Int. 2019;2019:1-11.

DOI: 10.1155/2019/4805853.

Shahbazi F, Sadighi S, Dashti‐Khavidaki S, Shahi F, Mirzania M, Abdollahi A, et al. Effect of silymarin administration on cisplatin nephrotoxicity: report from a pilot, randomized, double‐blinded, placebo‐controlled clinical trial. Phytother Res. 2015;29(7):1046-1053.

DOI: 10.1002/ptr.5345.

Hakiminia B, Goudarzi A, Moghaddas A. Has vitamin E any shreds of evidence in cisplatin‐induced toxicity. J Biochem Mol Toxicol. 2019;33(8):e22349,1-15.

DOI:10.1002/jbt.22349.

Wang Y, Jin B, Ai F, Duan C, Lu Y, Dong T, et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol. 2012;69(5):1213-1220.

DOI: 10.1007/s00280-012-1828-8.

Ko JW, Shin NR, Jung TY, Shin IS, Moon C, Kim SH, et al. Melatonin attenuates cisplatin-induced acute kidney injury in rats via induction of anti-aging protein, Klotho. Food Chem Toxicol. 2019; 129:201-210.

DOI: 10.1016/j.fct.2019.04.049.

Hara M, Yoshida M, Nishijima H, Yokosuka M, Iigo M, Ohtani‐Kaneko R, et al. Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin‐induced nephrotoxicity in rats. J Pineal Res. 2001;30(3):129-138.

DOI: 10.1034/j.1600-079x.2001.300301.x.

Haghi-Aminjan H, Farhood B, Rahimifard M, Didari T, Baeeri M, Hassani S, et al. The protective role of melatonin in chemotherapy‐induced nephrotoxicity: a systematic review of non-clinical studies. Expert Opin Drug Metab Toxicol. 2018;14(9):937-950.

DOI: 10.1080/17425255.2018.1513492.

Kim JW, Jo J, Kim JY, Choe M, Leem J, Park JH. Melatonin attenuates cisplatin-induced acute kidney injury through dual suppression of apoptosis and necroptosis. Biology (Basel). 2019;8(3):64,1-10.

DOI: 10.3390/biology8030064.

Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ, et al. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther. 2012;11(4):293-303.

DOI: 10.1177/1534735411425484.

Pourhanifeh MH, Sharifi M, Reiter RJ, Davoodabadi A, Asemi Z. Melatonin and non-small cell lung cancer: new insights into signaling pathways. Cancer Cell Int. 2019;19(1):131-137.

DOI: 10.1186/s12935-019-0853-7.

Common Terminology Criteria forAdverse Events V5.0 (CTCAE). 2020. Available from: http://ctep.cancer.gov/protocoldevelopment/ electronic_applications/ctc.htm, (Accessed on June 4, 2019). Last updated 2021.

Lin CY, Chen YC. Acute kidney injury classification: AKIN and RIFLE criteria in critical patients. World J Crit Care Med. 2012;1(2): 40-45.

DOI:10.5492/wjccm.v1.i2.40.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245.

DOI: 10.1038/clpt.1981.154.

Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81(5):442-448.

DOI: 10.1038/ki.2011.379.

Ghadrdan E, Sadighi S, Ebrahimpour S, Abdollahi A, Hadjibabaei M, Gholami K, et al. The effect of melatonin on cisplatin-induced nephrotoxicity: a pilot, randomized, double-blinded, placebo-controlled clinical trial. Eur J Integr Med. 2020;34:101065,1-7.

DOI: 10.1016/j.eujim.2020.101065.

Kilic U, Kilic E, Tuzcu Z, Tuzcu M, Ozercan IH, Yilmaz O, et al. Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-2/HO-1 pathway. Nutr Metab (Lond). 2013;10(1):7-14.

DOI: 10.1186/1743-7075-10-7.

Goudarzi M, Khodayar MJ, Hosseini Tabatabaei SMT, Ghaznavi H, Fatemi I, Mehrzadi S. Pretreatment with melatonin protects against cyclophosphamide‐induced oxidative stress and renal damage in mice. Fundam Clin Pharmacol. 2017;31(6):625-635.

DOI: 10.1023/b:cbto.0000013342.17370.16

Ahmadiasl N, Banaei S, Alihemmati A. Combination antioxidant effect of erythropoietin and melatonin on renal ischemia-reperfusion injury in rats. Iran J Basic Med Sci. 2013;16(12):1209-1216.

DOI: 10.22038/IJBMS.2013.1978.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.